Autologous platelet-rich plasma versus autologous serum in treatment of dry eye disease

This work aimed to assess the efficacy and safety of autologous PRP versus AS in treatment of moderate to severe DED. A prospective, comparative, randomized controlled clinical trial involved 96 eyes of 48 cases with moderate and severe DED divided into 3 groups (16 patients each). Group 1 received PRP eye drops, Group 2 received AS eye drops and Group 3 (control group) received sodium hyaluronate eye drops. All participants were subjected to Ocular Surface Disease Index (OSDI), tear film break-up time (TBUT), Schirmer 1 test, ocular surface staining, and best corrected visual acuity (BCVA). PRP and AS showed significant improvements in all parameters compared to sodium hyaluronate, with greater improvement in OSDI, Schirmer test and ocular surface staining with PRP compared to AS. PRP and AS have high safety and efficacy rates in moderate and severe DED, providing better symptom relief and clinical improvements than artificial tears with superiority for PRP over AS.